Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 363

1.

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.

Sfikakis PP, Boletis JN, Tsokos GC.

Curr Opin Rheumatol. 2005 Sep;17(5):550-7. Review.

PMID:
16093832
2.

B-cell-targeted therapy for systemic lupus erythematosus.

Sabahi R, Anolik JH.

Drugs. 2006;66(15):1933-48.

PMID:
17100405
3.

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.

J Rheumatol. 2008 May;35(5):826-33. Epub 2008 Apr 1.

PMID:
18398943
4.
5.

[B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].

Tanaka Y.

Yakugaku Zasshi. 2009 Jun;129(6):675-9. Review. Japanese.

6.
7.

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.

Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, Koike T.

Mod Rheumatol. 2007;17(3):191-7. Epub 2007 Jun 20.

PMID:
17564773
8.

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.

Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y.

Rheumatology (Oxford). 2005 Feb;44(2):176-82. Epub 2004 Oct 19.

9.

B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.

Kumar S, Benseler SM, Kirby-Allen M, Silverman ED.

Pediatrics. 2009 Jan;123(1):e159-63. doi: 10.1542/peds.2008-2361. Epub 2008 Dec 15.

PMID:
19074962
10.

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.

Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A.

Lupus. 2010 Feb;19(2):213-9. doi: 10.1177/0961203309351541. Epub 2009 Dec 4.

PMID:
19965944
11.

Rituximab therapy for childhood-onset systemic lupus erythematosus.

Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B; French Pediatric-Onset SLE Study Group.

J Pediatr. 2006 May;148(5):623-627. Erratum in: J Pediatr. 2006 Oct;149(4):586.

PMID:
16737873
12.

Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.

Chambers SA, Isenberg D.

Lupus. 2005;14(3):210-4. Review.

PMID:
15807198
13.

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.

Arthritis Rheum. 2007 Apr;56(4):1263-72.

14.

B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.

Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K.

Arch Dis Child. 2008 May;93(5):401-6. Epub 2007 Nov 26.

PMID:
18039744
15.

Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.

Tew GW, Rabbee N, Wolslegel K, Hsieh HJ, Monroe JG, Behrens TW, Brunetta PG, Keir ME.

Lupus. 2010 Feb;19(2):146-57. doi: 10.1177/0961203309350752. Epub 2009 Nov 27.

PMID:
19946034
16.

B cells as therapeutic targets for rheumatic diseases.

Looney RJ, Anolik J, Sanz I.

Curr Opin Rheumatol. 2004 May;16(3):180-5. Review.

PMID:
15103242
17.

Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.

El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP.

J Pediatr. 2007 Apr;150(4):376-82.

PMID:
17382113
18.

Effective B cell depletion with rituximab in the treatment of autoimmune diseases.

Kneitz C, Wilhelm M, Tony HP.

Immunobiology. 2002 Dec;206(5):519-27.

PMID:
12607727
19.

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.

Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.

Ann Rheum Dis. 2008 Jul;67(7):1011-6. Epub 2007 Oct 25.

PMID:
17962238
20.

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.

Arthritis Rheum. 2005 Feb;52(2):501-13.

Items per page

Supplemental Content

Write to the Help Desk